Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

BM Ellingson; ER Gerstner; Marion Smits; RY Huang; R Colen; LE Abrey; DT Aftab; GM Schwab; C Hessel; RJ Harris; A Chakhoyan; Renske Gahrmann; WB Pope; K Leu; C Raymond; DC Woodworth; John de Groot; PY Wen; TT Batchelor; Martin van den Bent; TF Cloughesy

doi:10.1158/1078-0432.ccr-16-2844

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

BM Ellingson
, ER Gerstner
, Marion Smits
, RY Huang
, R Colen
, LE Abrey
, DT Aftab
, GM Schwab
, C Hessel
, RJ Harris
, A Chakhoyan
, Renske Gahrmann
, WB Pope
, K Leu
, C Raymond
, DC Woodworth
, John de Groot
, PY Wen
, TT Batchelor
, Martin van den Bent

TF Cloughesy

Research output: Contribution to journal › Article › Academic › peer-review

63 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	5745-5756
Number of pages	12
Journal	Clinical Cancer Research
Volume	23
Issue number	19
DOIs	https://doi.org/10.1158/1078-0432.ccr-16-2844
Publication status	Published - 2017

Research programs

EMC NIHES-03-30-02

Access to Document

10.1158/1078-0432.ccr-16-2844

http://hdl.handle.net/1765/102560

Cite this

Ellingson, BM., Gerstner, ER., Smits, M., Huang, RY., Colen, R., Abrey, LE., Aftab, DT., Schwab, GM., Hessel, C., Harris, RJ., Chakhoyan, A., Gahrmann, R., Pope, WB., Leu, K., Raymond, C., Woodworth, DC., de Groot, J., Wen, PY., Batchelor, TT., ... Cloughesy, TF. (2017). Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 23(19), 5745-5756. https://doi.org/10.1158/1078-0432.ccr-16-2844

@article{47945865bfbe4036af1616777cd91bd7,

title = "Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials",

author = "BM Ellingson and ER Gerstner and Marion Smits and RY Huang and R Colen and LE Abrey and DT Aftab and GM Schwab and C Hessel and RJ Harris and A Chakhoyan and Renske Gahrmann and WB Pope and K Leu and C Raymond and DC Woodworth and \{de Groot\}, John and PY Wen and TT Batchelor and \{van den Bent\}, Martin and TF Cloughesy",

year = "2017",

doi = "10.1158/1078-0432.ccr-16-2844",

language = "Undefined/Unknown",

volume = "23",

pages = "5745--5756",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "19",

}

Ellingson, BM, Gerstner, ER, Smits, M, Huang, RY, Colen, R, Abrey, LE, Aftab, DT, Schwab, GM, Hessel, C, Harris, RJ, Chakhoyan, A, Gahrmann, R, Pope, WB, Leu, K, Raymond, C, Woodworth, DC, de Groot, J, Wen, PY, Batchelor, TT, van den Bent, M & Cloughesy, TF 2017, 'Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials', Clinical Cancer Research, vol. 23, no. 19, pp. 5745-5756. https://doi.org/10.1158/1078-0432.ccr-16-2844

TY - JOUR

T1 - Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials

AU - Ellingson, BM

AU - Gerstner, ER

AU - Smits, Marion

AU - Huang, RY

AU - Colen, R

AU - Abrey, LE

AU - Aftab, DT

AU - Schwab, GM

AU - Hessel, C

AU - Harris, RJ

AU - Chakhoyan, A

AU - Gahrmann, Renske

AU - Pope, WB

AU - Leu, K

AU - Raymond, C

AU - Woodworth, DC

AU - de Groot, John

AU - Wen, PY

AU - Batchelor, TT

AU - van den Bent, Martin

AU - Cloughesy, TF

PY - 2017

Y1 - 2017

U2 - 10.1158/1078-0432.ccr-16-2844

DO - 10.1158/1078-0432.ccr-16-2844

M3 - Article

SN - 1078-0432

VL - 23

SP - 5745

EP - 5756

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 19

ER -